BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24510381)

  • 21. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma.
    Fleming RY; Asmar L; Buzdar AU; McNeese MD; Ames FC; Ross MI; Singletary SE
    Ann Surg Oncol; 1997 Sep; 4(6):452-61. PubMed ID: 9309333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes of curative-intent multimodal management of chemorefractory nonmetastatic inflammatory breast cancer.
    Loap P; Nicaise B; Laki F; Loirat D; Pierga JY; Fourquet A; Kirova Y
    Strahlenther Onkol; 2023 Jan; 199(1):30-37. PubMed ID: 35648170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Management of inflammatory breast cancer after neo-adjuvant chemotherapy].
    Abrous-Anane S; Savignoni A; Daveau C; Pierga JY; Gautier C; Reyal F; Dendale R; Campana F; Kirova Y; Fourquet A; Bollet MA
    Cancer Radiother; 2011 Dec; 15(8):654-62. PubMed ID: 21820933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of CNS metastases and survival in patients with inflammatory breast cancer.
    Uemura MI; French JT; Hess KR; Liu D; Raghav K; Hortobagyi GN; Arun BK; Valero V; Ueno NT; Alvarez RH; Woodward WA; Debeb BG; Moulder SL; Lim B; Tripathy D; Ibrahim NK
    Cancer; 2018 Jun; 124(11):2299-2305. PubMed ID: 29579338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.
    Fouad TM; Kogawa T; Liu DD; Shen Y; Masuda H; El-Zein R; Woodward WA; Chavez-MacGregor M; Alvarez RH; Arun B; Lucci A; Krishnamurthy S; Babiera G; Buchholz TA; Valero V; Ueno NT
    Breast Cancer Res Treat; 2015 Jul; 152(2):407-16. PubMed ID: 26017070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.
    Sood BM; Jones J; Gupta S; Khabele D; Guha C; Runowicz C; Goldberg G; Fields A; Anderson P; Vikram B
    Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):208-16. PubMed ID: 12909235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative Radiation Therapy for Chemorefractory Localized Inflammatory Breast Cancer.
    Rogé M; Kirova Y; Loap P; Amar S; Servagi S; Nebbache R; Rivin Del Campo E; Clatot F; Thureau S; Thariat J
    Pract Radiat Oncol; 2023; 13(6):e491-e498. PubMed ID: 37295726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammatory breast cancer-comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response.
    Horváth Z; Torday L; Hitre E; Ganofszky E; Juhos E; Czeglédi F; Urbán L; Polgár C; Láng I; Eckhardt S; Kásler M
    Pathol Oncol Res; 2011 Sep; 17(3):541-50. PubMed ID: 21153723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
    Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
    Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammatory breast cancer in the Netherlands; improved survival over the last decades.
    van Uden DJ; Bretveld R; Siesling S; de Wilt JH; Blanken-Peeters CF
    Breast Cancer Res Treat; 2017 Apr; 162(2):365-374. PubMed ID: 28138891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery.
    Rosso KJ; Tadros AB; Weiss A; Warneke CL; DeSnyder S; Kuerer H; Ueno NT; Stecklein SR; Woodward WA; Lucci A
    Ann Surg Oncol; 2017 Oct; 24(10):2981-2988. PubMed ID: 28766220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
    Pierga JY; Bidard FC; Autret A; Petit T; Andre F; Dalenc F; Levy C; Ferrero JM; Romieu G; Bonneterre J; Lerebours F; Bachelot T; Kerbrat P; Campone M; Eymard JC; Mouret-Reynier MA; Gligorov J; Hardy-Bessard AC; Lortholary A; Soulie P; Boher JM; Proudhon C; Charafe-Jaufret E; Lemonnier J; Bertucci F; Viens P
    Ann Oncol; 2017 Jan; 28(1):103-109. PubMed ID: 28177480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of age on the outcome of patients treated with radiotherapy for mucoepidermoid carcinoma (MEC) of the salivary glands in the head and neck: A 15-year single-center experience.
    Akbaba S; Heusel A; Mock A; Held T; Lang K; Hoerner-Rieber J; Forster T; Katayama S; Kargus S; Rieken S; Plinkert P; Herfarth K; Debus J; Adeberg S
    Oral Oncol; 2019 Oct; 97():115-123. PubMed ID: 31494395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
    White R; Dinneen T; Makris A
    Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy.
    Low JA; Berman AW; Steinberg SM; Danforth DN; Lippman ME; Swain SM
    J Clin Oncol; 2004 Oct; 22(20):4067-74. PubMed ID: 15483018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors in patients with isolated recurrences of breast cancer (stage IV-NED).
    Juan O; Lluch A; de Paz L; Prósper F; Azagra P; Marugán I; Martínez-Agulló A; Garcia-Conde J
    Breast Cancer Res Treat; 1999 Jan; 53(2):105-12. PubMed ID: 10326787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modern outcomes of inflammatory breast cancer.
    Rehman S; Reddy CA; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):619-24. PubMed ID: 22445003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Locoregional Treatment of the Primary Tumor in Patients With De Novo Stage IV Breast Cancer: A Radiation Oncologist's Perspective.
    Choi SH; Kim JW; Choi J; Sohn J; Kim SI; Park S; Park HS; Jeong J; Suh CO; Keum KC; Kim YB; Lee IJ
    Clin Breast Cancer; 2018 Apr; 18(2):e167-e178. PubMed ID: 28689012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer.
    Wang J; Suri JS; Allen PK; Liao Z; Komaki R; Ho L; Hofstetter WL; Lin SH
    Am J Clin Oncol; 2016 Jun; 39(3):228-35. PubMed ID: 24710122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics.
    Biswas T; Jindal C; Fitzgerald TL; Efird JT
    Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30621221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.